Loading...
XNAS
PRPO
Market cap36mUSD
Dec 05, Last price  
24.02USD
1D
-2.40%
1Q
35.40%
IPO
-99.11%
Name

Precipio Inc

Chart & Performance

D1W1MN
XNAS:PRPO chart
P/E
—
P/S
2.31
EPS
—
Div Yield, %
—
Shrs. gr., 5y
38.77%
Rev. gr., 5y
38.55%
Revenues
16m
+5.05%
25,828,00023,415,00023,176,00023,993,00022,023,00020,048,00031,971,00031,480,00027,544,00027,083,0001,653,0001,557,0001,723,0002,864,0003,127,0006,092,0008,849,0009,412,00015,197,00015,965,000
Net income
-4m
L-26.70%
-14,993,000-3,431,000-2,107,000-495,000-1,920,000-3,134,000-9,782,000-8,327,000-15,987,000-13,942,000-32,954,000-7,616,000-20,694,000-15,694,000-13,243,000-12,230,000-8,550,000-12,203,000-5,853,000-4,290,000
CFO
439k
P
-3,627,000-1,212,000-2,939,000-413,0001,267,000-1,718,000220,000-10,204,000-8,473,000-13,702,000-12,378,000-3,550,000-6,690,000-6,754,000-9,141,000-7,434,000-6,577,000-7,721,000-3,559,000439,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
URL
http://www.precipiodx.com/
IPO date
Jul 18, 2000
Employees
53
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT